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More than 50% of transitional cell carcinomas of the bladder show loss of heterozygosity of a region span-
ning the TSC1 locus at 9q34 and mutations of TSC1 have been identiﬁed in 14.5% of tumours. These comprise
nonsense mutations, splicing mutations, small deletions and missense mutations. Missense mutations are
only rarely found in the germline in TSC disease. Therefore, we have examined six somatic missense
mutations found in bladder cancer to determine whether these result in loss of function. We describe loss
of function via distinct mechanisms. Five mutations caused mutually exclusive defects at mRNA and protein
levels. Of these, two mutations caused pre-mRNA splicing errors that were predicted to result in premature
protein truncation and three resulted in markedly reduced stability of exogenous TSC1 protein. Primary
tumours with aberrant TSC1 pre-mRNA splicing were conﬁrmed as negative for TSC1 expression by immu-
nohistochemistry. Expression was also signiﬁcantly reduced in a tumour with a TSC1 missense mutation
resulting in diminished protein half-life. A single TSC1 missense mutation identiﬁed in a tumour with retained
heterozygosity of the TSC1 region on chromosome 9 caused an apparently TSC2- and mTOR-independent
localization defect of the mutant protein. We conclude that although TSC1 missense mutations do not play
a major role in causation of TSC disease, they represent a signiﬁcant proportion of somatic loss of function
mutations in bladder cancer.
INTRODUCTION
Tuberous Sclerosis Complex (TSC) is an autosomal dominant
tumour suppressor gene syndrome with an incidence of 1 in
6000–10 000 births. TSC is characterized by the development
of benign growths, called hamartomas, in the kidneys, heart,
brain and skin, and patients present clinically with a variety
of developmental disorders (1). TSC is caused by mutations
affecting either of the tumour suppressor genes TSC1 or
TSC2. TSC1 on chromosome 9q34 encodes hamartin (2) and
TSC2 on chromosome 16p13.3 encodes tuberin (3). Approxi-
mately half of large TSC families show linkage to 9q34 and
half to 16p13.3 (4–6). Tumour development in TSC patients
is thought to occur as the result of a somatic ‘second-hit’ in
either TSC1 or TSC2, according to Knudson’s tumour suppres-
sor model (7). Loss of heterozygosity (LOH) of TSC1 or TSC2
has been reported in some TSC hamartomas, such as renal
angiomyolipomas. However, loss of the wild-type allele in
brain lesions is rare, suggesting the possibility of tissue-
speciﬁc haploinsufﬁciency of TSC genes (8–10).
Co-localization and co-immunoprecipitation of TSC1 and
TSC2 in mammalian cells (11,12) and direct binding in
yeast two-hybrid assays provide a tentative explanation for
the similar disease phenotype in TSC patients with mutations
in either TSC1 or TSC2 genes (2,13). Functionally, the TSC1/
TSC2 complex is positioned at the centre of multiple growth
signalling pathways and is a key integrator of signals control-
ling protein translation and cell growth (14). Activation of the
TSC1/TSC2 complex in growth-limiting conditions attenuates
signalling through mTOR via speciﬁc GTPase activating
protein (GAP) activity of TSC2 towards RHEB (15,16).
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TSC, studies in this laboratory and others have implicated
loss of function of TSC1 in bladder tumorigenesis (17–19).
Loss of heterozygosity (LOH) for markers on chromosome 9
is observed in more than 50% of bladder tumours of all
grades and stages (20) and sub-chromosomal LOH analyses
have identiﬁed the TSC1 locus at 9q34 as a common critical
region of deletion between markers D9S149 and D9S66
(19,21–23). To date, we have screened 154 bladder tumours
by ﬂuorescent single strand conformation polymorphism
(F-SSCP) analysis and direct sequencing, and found an overall
mutation frequency of 14.5%. The mutation spectrum comprises
nonsense (35%), missense (26%), frameshift (26%), in-frame
deletions (3%) and splicing (10%) mutations (24) (Platt et al.,
in preparation). In all cases but one, TSC1 missense mutations
were tumour-speciﬁc somatic events. TSC1 is the only gene
on 9q that has been found to be mutated in bladder tumours,
and may therefore be the critical gene on this chromosome
arm implicated in .50% of all bladder tumours.
Missense mutations of TSC1 have not routinely been con-
ﬁrmed as functionally inactivating in TSC disease, though
two recent reports provide evidence that in a few cases these
are likely to be disease-causing (25,26). Here we sought to
determine whether the TSC1 missense mutations identiﬁed in
bladder tumours constituted inactivating mutations. We antici-
pated that discrete amino acid changes of mutant proteins
might allow the identiﬁcation of functionally important resi-
dues. Wild-type and mutant TSC1 constructs were retrovirally
delivered into TSC1-null bladder tumour cell lines and func-
tionally characterized. All somatic TSC1 missense mutations
perturbed TSC1 function by causing aberrant splicing,
protein instability or protein mislocalization. Defects were
conﬁrmed in primary tumours by RT–PCR analysis of
mutant transcripts and immunohistochemical analysis.
RESULTS
Missense mutations of TSC1 identiﬁed in bladder tumours
Previously, we identiﬁed 8 mutations including 2 missense
mutations in a series of 62 bladder tumours (24). Screening
of an additional 92 tumours (Platt et al., in preparation) ident-
iﬁed an additional 15 mutations of which 4 were missense
mutations. In total, therefore, 6 missense mutations have
been identiﬁed in 154 tumours, representing 26% of all
mutations found (Table 1). Mutations were determined as
tumour-speciﬁc by genotyping of paired tumour and blood
samples. 1250C.T (Thr417Ile) was previously described in
the germline in TSC disease in Japanese patients, but was
not conﬁrmed as causative of TSC (27,28). 1250C.T was
also identiﬁed in our laboratory in the patient’s constitutional
DNA, and the tumour sample retained heterozygosity for
microsatellite markers at the TSC1 gene locus (24). Threonine
417 was previously identiﬁed as a site of CDK1-dependent
phosphorylation (29). To determine the biological signiﬁcance
of this variant, 1250C.T (Thr417Ile) was characterized here
alongside tumour-speciﬁc missense mutations. Five of six
other tumours with TSC1 missense mutations showed LOH
for markers at the TSC1 locus (Table 1). There was no
relationship between mutation and tumour stage or grade.
Missense mutations were predominantly N-terminal but did
not localize to a common functional domain (Fig. 1).
To assess possible functional implications of amino acid
substitutions, conservation of missense mutant residues was
determined in TSC1 orthologs. His68, Phe158 and Phe216
were conserved among Rattus, Mus, Drosophila, Fugu and
Gallus orthologs. His105, His206 and Thr417 differed only in
Drosophila, which shares 31% identity with human TSC1.
Ser35 differed in Drosophila, Fugu and Gallus orthologs.
According to the BLOSUM62 scoring matrix (30), His68Arg
and His105Arg substitutions are considered conservative.
Ser35Cys, His206Asp and Thr417Ile are less conservative and
Phe158Cys and Phe216Asp are least conservative (Table 1).
Re-expression of missense mutant TSC1 proteins in
TSC1-null urothelial cells
We anticipated that missense mutations might lead to loss of
function at the amino acid level. Thus, our initial approach
was to express wild-type and missense mutant TSC1 cDNAs
in TSC1-null bladder cell lines and investigate function of
the mutant proteins. Missense mutant proteins were C-
terminally FLAG- or GFP-tagged, expressed in 97-1 and
HCV29 cells and characterized for TSC2 binding activity,
and mTOR suppressive activity in nutrient-starved conditions.
Expression of mutant proteins was investigated by immuno-
blotting following retroviral transduction and selection of neo-
mycin resistant mass cell populations. Expression levels of
mutant proteins were markedly different; Ser35Cys,
His105Arg, Phe216Asp and Thr417Ile were expressed at
high levels similar to wild-type protein, whereas His68Arg
and Phe158Cys were much reduced and His206Asp was not
detected (Fig. 2A). Repeated independent infections of these
two cell lines and of telomerase-immortalized normal human
urothelial cells (TERT-NHUC) and assessment of mass popu-
lations of cells following selection resulted in entirely reprodu-
cible expression levels of all mutant proteins (data not shown).
The transcription of missense RNA was conﬁrmed by real
time RT–PCR and uniform levels of wild-type and missense
transcripts were detected (Fig. 2B). The consistently reduced
or absent protein expression of His68Arg and Phe158Cys
and His206Asp missense mutant forms despite the presence
of RNA expression suggested possible effects of these mis-
sense changes on protein stability.











104C.G 3 Ser35Cys 21T 1 G3 Loss
203A.G 4 His68Arg 0 T2 G2 Loss
314A.G 5 His105Arg 0 Ta G2 Loss
473T.G 6 Phe158Cys 22T a G1 Loss
616C.G 7 His206Asp 21T a G1 Loss
648T.A 7 Phe216Ala 22T a G2 Retention
1250C.T
a 12 Thr417lle 21T 2 G3 Retention
aThis variant was also found in the patient’s normal DNA.
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The interaction between TSC1 and TSC2 appears to be
important in maintaining the stability of each of the proteins.
TSC1/TSC2 binding speciﬁcally augments TSC2 expression
by limiting its ubiquitination (31,32). TSC2 GAP activity
towards RHEB deﬁnes TSC1/2 mediated control of mTOR
signalling, and phosphorylation of downstream effectors of
Figure 1. Positions of amino acid substitutions in relation to described functional domains of hamartin.
Figure 2. (A) Immunoblot showing levels of wild-type and mutant TSC1-FLAG proteins and endogenous TSC2 in 97-1 cell lines. (B) Measurement of TSC1
RNA levels by real time RT–PCR analysis of wild-type and mutant TSC1-FLAG mRNA transcript levels in 97-1 cell lines. RT2ve is reverse transcriptase-
negative control, NTC is no template control. TSC1 expression is standardized to SDHA and normalized to the 97-1 Neo cell line.
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in cells lacking TSC1 or TSC2 (33–35). Where expressed,
missense mutant TSC1 proteins stabilized TSC2 levels in
97-1 cells (Fig. 2A) and co-immunoprecipitated with it
(Fig. 3A). However, our data cannot exclude minor effects
on interaction or TSC2 stability.
While His206Asp-FLAG was undetected in transduced 97-1
cells, we were able to achieve low-level expression of
His206Asp-GFP in HCV29 cells, suggesting some stabilizing
effect of the GFP tag. TSC2 co-immunoprecipitation and S6
phosphorylation assays were not accurately quantitative, but
expression of all missense mutant proteins in TSC1-null cells
reduced S6 phosphorylation in amino acid starved conditions,
relative to vector alone (Fig. 3B), indicating that none of
these mutant forms of TSC1 abolish interaction with TSC2.
Aberrant RNA splicing caused by TSC1 missense mutations
High-level expression and TSC2 binding activity of TSC1
Ser35Cys, His105Arg and Phe216Ala proteins suggested no
functional effect of amino acid substitutions caused by
104C.G, 314A.G and 648T.A missense mutations.
However, the expression of proteins from exogenous missense
cDNAs did not allow the assessment of possible effects of
mutations at the pre-mRNA level. We speculated that TSC1
missense mutations may cause loss of function through
introduction of splicing errors in mutant transcripts in vivo.
Therefore, wild-type and missense mutant TSC1 pre-mRNA
sequences were screened for effects of mutations on splice
site deﬁnition using the neural network algorithm (http://
www.fruitﬂy.org/seq_tools/splice.html).
Interestingly, signiﬁcant differences were seen between
splice site scores of wild-type and 104C.G and 314A.G
TSC1 transcripts. The 104C.G mutation, positioned 3 bp
upstream of the TSC1 exon 3/4 junction, resulted in a reduced
exon 3/4 splice motif score. The 314A.G mutation resulted
in the introduction of a high-scoring 50 donor splice site,
immediately upstream of the A/G transversion, by generation
of a novel consensus splice motif. No differences in splice site
scores were observed between wild-type and 648T.Ao r
1250C.T transcripts or between wild-type and mutant tran-
scripts that generated low exogenous protein expression.
To examine splicing of missense mutant TSC1 transcripts,
fragments spanning the mutation site and ﬂanking intron/exon
junctions were ampliﬁed from respective tumour cDNAs by
RT–PCR and sequenced. An RT–PCR product reproducibly
ampliﬁed from cDNA of the tumour containing 104C.G
showed increased electrophoretic mobility relative to a control
fragment ampliﬁed from TERT-NHUC cDNA (Fig. 4A).
Sequencing of the tumour product revealed use of a cryptic 50
donor site in exon 4, the adjacent downstream exon to the
104C.G mutant exon (Supplementary Material, Fig. S1). The
reduced splice motif score at the exon 3/4 junction was shown to
have no effect on exon 3/4 splicing. If translated, this 104C.G
mutant transcript would generate 26 new amino acids from an
alternate reading frame and truncate prematurely at residue 79.
A faster migrating band was also reproducibly ampliﬁed
from cDNA of the tumour containing 314A.G (Fig. 4B),
compared to control TERT-NHUC cDNA. Sequence analysis
of PCR products revealed a 50-nucleotide deletion in the tran-
script generated from the missense allele. The 314A.G
mutation created a de novo 50 donor splice site immediately
upstream of 314A.G and resulted in the splicing of 50
nucleotides from the 30 end of exon 5. The effect seen at the
mRNA level was entirely consistent with the prediction
made by in silico analysis. If translated, the 314A.G
mutant transcript is expected to generate two new C-terminal
amino acids and truncate prematurely at residue 107.
Exon skipping through introduction of a de novo 50 splice
site by point mutation is a relatively well-described mechan-
ism of aberrant pre-mRNA splicing (36–38). No normal tran-
script was ampliﬁed from cDNA from tumours containing
TSC1 104C.G or 314A.G mutations, suggesting that all
splicing occurs via the novel sites. The abundance of missense
transcripts appeared lower than normal transcript by semi-
quantitative RT–PCR, when standardized to HPRT.
However, by real time RT–PCR, TSC1 transcript abundance
was relatively higher in tumours with TSC1 missense
mutations causing transcript splicing or protein stability
defects, than in uncultured or cultured TERT-NHUC, when
standardized to SDHA (data not shown).
Missense mutant TSC1 proteins exhibit reduced
protein stability
The demonstration of consistently low-level exogenous
protein expression, despite uniform mRNA transcript
Figure 3. (A) Immunoblot showing TSC1 and TSC2 in 97-1 Neo control and
FLAG-tagged wild-type and mutant TSC1 cell line lysates immunoprecipi-
tated with anti-TSC1 and non-speciﬁc mouse IgM antibodies. (B) Immunoblot
showing expression levels of GFP-tagged wild-type and missense mutant
TSC1 protein in HCV29 cell lines. Also shown are levels of S6 phosphoryl-
ation in transiently amino acid starved cells.
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Phe158Cys and His206Asp mutant proteins. By inhibiting
protein synthesis with cycloheximide, we determined that
His68Arg, Phe158Cys and His206Asp mutant proteins were
turned-over relatively faster than wild-type TSC1, in a
proteasome-dependent manner (Fig. 5 A and B and data not
shown). Moreover, by
35S labelling, we were able to show
that His68Arg, Phe158Cys and His206Asp proteins had
markedly shorter half-lives than wild-type TSC1 (Fig. 5C).
Phe216Ala TSC1 protein shows altered localization
Previous studies have described a granular, cytoplasmic local-
ization of endogenous TSC1 in vitro and in vivo and also of
overexpressed TSC1 in COS-7 cells (39–41). Localization
of monomeric TSC1 and of TSC1 complexed with TSC2 is
likely inﬂuenced by culture conditions given that components
of the Akt-mTOR signalling cascade are membrane localized
when activated. In addition, TSC2 is reported to shuttle into
the nucleus in a cell cycle and phosphorylation-dependent
manner (42–44).
It was anticipated that the characterization of discrete mis-
sense amino acid changes may offer insight into potentially
mTOR-independent or bladder-speciﬁc functions of TSC1.
Our results indicated that TSC1 104C.G, 203A.G,
314A.G, 473T.G and 616C.G missense mutations cause
loss of function by generic mechanisms of altered message
or reduced protein stability. However, sequencing of RT–
PCR products ampliﬁed from cDNA from the tumour contain-
ing the TSC1 648T.A mutation showed no altered splicing of
the mutant transcript. Also, at the protein level, Phe216Ala
was expressed at high levels similar to wild-type TSC1. The
substitution of a phenylalanine residue for an alanine residue
constitutes the loss of a high-molecular weight, hydrophobic
benzyl group and is assigned a non-conservative –2
BLOSUM62 score. The lack of effect on splicing or protein
stability raised the possibility that this mutation may cause a
defect in TSC1 protein function per se.
We determined the localization of GFP-tagged mutant pro-
teins in nutrient replete and deﬁcient conditions. Wild-type,
Phe216Ala, Ser35Cys, His68Arg and Thr417Ile proteins
were compared. In complete growth medium, wild-type
TSC1 and Ser35Cys, His68Arg and Thr417Ile mutant proteins
showed diffuse punctate cytoplasmic distribution with distinct
cytoplasmic foci. In amino acid deﬁcient medium, these pro-
teins became localized almost exclusively to large cytoplasmic
bodies. Intriguingly, the Phe216Ala substitution markedly
altered the localization of TSC1; Phe216Ala was exclusively
cytoplasmic and diffuse in full growth medium and did not
redistribute to discrete bodies in amino acid deﬁcient con-
ditions (Fig. 6). However, it was shown to stabilize and to
co-immunoprecipitate with endogenous TSC2, and to attenu-
ate growth signalling through mTOR in starved conditions
(Fig. 3B). These observations were reproduced in TSC1-
transduced 97-1 and HCV29 cell lines and TERT-NHUC
and suggest that localization of TSC1 to cytoplasmic foci is
not a requirement for TSC2 binding or negative regulation
of mTOR. Also, defective localization of Phe216Ala is
likely TSC2- and mTOR-independent, possibly suggesting
an independent function of TSC1 at cytoplasmic foci.
Unlike the other ﬁve tumours with missense mutations, the
tumour containing the TSC1 648T.A mutation did not show
LOH of 9q, as conﬁrmed by analysis of pure microdissected
tumour cell populations (data not shown). Both normal
and mutant alleles were detected by sequencing of tumour
cDNA.
TSC1 protein expression in bladder tumour tissues
To examine the effects of pre-mRNA splicing defects and
protein stability defects caused by missense mutations at the
tumour level, TSC1 mutant and wild-type tumours were
screened for expression of TSC1 protein by immunohisto-
chemistry. Sensitivity and speciﬁcity of a rabbit monoclonal
anti-TSC1 antibody was conﬁrmed by staining of
parafﬁn-embedded pellets of TSC1-null HCV29 cells and
HCV29 in which wild-type TSC1 had been re-expressed
Figure 4. Semi quantitative RT–PCR analysis of TSC1 RNA in normal urothelial cells and TSC1 mutant tumour samples, showing increased electrophoretic
mobility of RT–PCR products ampliﬁed from cDNA from tumours containing TSC1 104C.G( A) and 314A.G( B) missense mutations. Controls are ampliﬁca-
tion reactions using RT þve (þ) and RT2ve (2) cDNA from pooled TERT-NHUC. Lower panels show HPRT RT–PCR products. Also shown are schematic
representations of aberrant splicing events associated with TSC1 104C.G (A) and TSC1 314A.G (B) mutations.
2010 Human Molecular Genetics, 2008, Vol. 17, No. 13(Fig. 7A and D). Normal ureter showed strong cytoplasmic
TSC1 expression in the urothelium (Fig. 7E). Tumours with
wild-type TSC1 showed strong cytoplasmic staining
(Fig. 7F), and a tumour with a TSC1 73–77D 5 small deletion
causing premature truncation at residue 27, showed no TSC1
expression (Fig. 7C). Both tumours with homozygous TSC1
missense mutations causing pre-mRNA splicing defects were
negative for TSC1 expression (Fig. 7G and H). Figure 7H
shows normal urothelium with strong TSC1 staining adjacent
to immunonegative TSC1 314A.G mutant tumour cells. The
648T.A (Phe216Ala) mutant tumour showed moderate TSC1
expression consistent with normal stability of the Phe216Ala
protein and retention of chromosome 9q heterozygosity in
the tumour (Fig. 7I). Of the three missense mutations
causing reduced protein stability (TSC1 203A.G, 473T.G
and 616C.G), tumour material was available only for the
616C.G (His206Asp) mutant sample. The 616C.G
mutation was identiﬁed from tumour material resected in
2003, and TSC1 expression was shown to be low in three
tumour resections from this patient in successive years
(Fig. 7J–L).
DISCUSSION
We have demonstrated that bladder tumour-derived TSC1 mis-
sense mutations result in loss of TSC1 function and that this
occurs via distinct mechanisms. An overall TSC1 mutation fre-
quency of 14.5% is found in bladder cancer (24) (Platt et al.,
in preparation) and missense mutations comprise 26% of
mutations found to date. The identiﬁcation of deleterious mis-
sense mutations in bladder tumours indicates a causative role
of loss of TSC1 function via this mechanism in bladder tumor-
igenesis. The vast majority of TSC1 mutations in TSC disease
are predicted to be protein truncating in nature, and no signiﬁ-
cant genotype/phenotype correlations have been observed
(2,5,45–48). Non-chain terminating TSC1 mutations (mis-
sense or in-frame deletions) are rare in TSC disease
(27,47,49,50) (www.LOVD.nl/TSC1). Although missense
mutations have been reported previously, most have not
been conﬁrmed as disease-causing. Several have been revealed
as rare polymorphisms or associated with other nonsense
mutations in the same patient (46,50). Others have been disre-
garded as potentially disease-causing on the basis of conserva-
tive amino acid changes, or have not been characterized
further (27,51). However, a recent publication by Jansen
et al. (26) that identiﬁed three missense mutations (L916R,
M224R and E412V) in affected individuals reported func-
tional analyses on two of these. It was reported that E412V
affected RNA splicing. Interestingly, in transfections of con-
structs of wild-type TSC1 and the M224R variant, the latter
showed lower levels of protein expression that were unable
to completely suppress S6 phosphorylation, results similar to
those described here for missense variants with reduced
protein half-life.
We have shown that two of six bladder tumour-derived mis-
sense mutations result in pre-mRNA splicing defects, three
lead to reduced stability of mutant proteins and intriguingly,
one mutation causes a TSC2- and mTOR-independent localiz-
ation defect of the mutant protein. Wild-type TSC1 showed a
granular cytoplasmic distribution in cells in full growth
medium and became localized almost exclusively to large
cytoplasmic bodies in amino acid starved cells. In contrast,
TSC1 was cytoplasmic and diffuse in serum-starved cells. Pre-
liminary results indicated that TSC1 bodies were dynamic,
non-aggresomal structures (data not shown). Interestingly,
the Phe216Ala substitution abolished the localization of
TSC1 to these bodies. As expected from its position outside
Figure 5. (A) Immunoblot showing turnover of wild-type and S35C and H68R
missense TSC1 proteins in cycloheximide (CHX)-treated cells. Cells were cul-
tured in full growth medium supplemented with 100 mg/ml CHX or DMSO
vehicle alone, and lysed at time-points indicated. Tubulin is shown as a
loading control. (B) Immunoblot showing stabilization of TSC1 H68R
protein levels by proteasome inhibition. Cells were cultured in full growth
medium and treated with 100 mg/ml CHX or DMSO vehicle alone or
pre-treated with 40 mM MG-132. (C) Half-lives of wild-type TSC1 and
His68Arg, Phe158Cys and His206Asp mutant proteins, as determined by
35S pulse chase analysis. Cells were pulsed with 250 mCi
35S in cysteine
and methionine-free medium and chased in full growth medium supplemented
with 200 nM cysteine and methionine. Cells were lysed at time-points as indi-
cated and lysates immunoprecipitated with an anti-TSC1 antibody. Degra-
dation of
35S-labelled TSC1 was determined of immunoprecipitated lysates
by SDS–PAGE analysis and autoradiography.
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retained TSC2 binding activity and mTOR suppressive
activity in amino acid starved conditions, suggesting that
localization of TSC1 to cytoplasmic foci was not a require-
ment for TSC2 binding or for suppression of mTOR signal-
ling. This may also suggest that TSC1 has a separable
function at cytoplasmic foci that is independent of TSC2
and independent of negative regulation of mTOR by TSC1/
TSC2. However, it is not clear whether the formation of
intensely staining bodies in conditions of over-expression of
TSC1 and/or TSC2 (39,52) is relevant to the normal physio-
logical condition. Further investigation of the function of
Phe216Ala is now required, ideally at levels of expression
that are closer to normal and in both TSC1-null cells and
those expressing endogenous wild-type TSC1.
Although the missense variant 1250C.T (T417I) was found
in the patient’s germline and this patient showed no symptoms
of TSC, we included this variant in our analyses as threonine
417 has previously been identiﬁed as a site of CDK1-dependent
phosphorylation (29). We found no evidence for a functional
defect and conclude that this represents a rare polymorphism.
As this patient was Japanese, as were both TSC patients in
whom this variant was reported previously (27,28), this rare
variant may be conﬁned to the Japanese population.
Evidence suggests that cis-acting mutations affecting
splicing of some tumour suppressor genes can have causal
roles in tumour initiation and progression (53). Predicted
and conﬁrmed effects of TSC-related and bladder tumour-
derived TSC1 missense changes on pre-mRNA splicing
reported here underscore the importance of using RNA-based
techniques, together with conventional mutation detection
methods, to effectively identify disease-causing mutations.
One of the mutations that deleteriously affected splicing
(104C.G) had an unexpected effect. The use of a cryptic 50
donor site in an adjacent downstream exon is a non-conventional
splicing event; disease-associated mutations at splice junctions
typically result in skipping of the mutant exon (38,54,55).
The 104C.G mutation was shown to reduce the exon 3 50
splice site motif score and to disrupt an enhancer sequence
spanning exon 3/4. 104C.G also disrupts a U1 snRNA-
binding motif, spanning the 50 splice site from position –3
to þ8 (Supplementary Material, Fig. S1). In combination
with a normally low-scoring exon 4 30 acceptor site, these
factors may result in reduced splicing efﬁciency of introns
3–4. Spliceosome assembly is directed by juxtaposed splicing
elements, and were introns 4–5 to splice ﬁrst, splicing
machinery at the 30 acceptor site of exon 4 may stimulate
recruitment of U1 snRNA to possible binding sites in exon
4, and result in use of a cryptic 50 donor site.
In bladder tumours as in TSC disease, nonsense, deletion
and frameshift TSC1 mutations result in premature protein
truncation and loss of protein function. We have now shown
that missense mutations cause loss of function by aberrant
splicing or reduced protein stability. The identiﬁcation of
tumour-speciﬁc TSC1 mutations in the context of chromosome
9 LOH argues strongly for a direct role of loss of TSC1 func-
tion in the aetiology of these tumours. These data are consist-
ent with TSC1 acting as a tumour suppressor gene in bladder
cancer in accordance with Knudsen’s two-hit hypothesis.
Biallelic inactivation of TSC1 or TSC2 may not be necessarily
required in some TSC-related tumours (9). The discrepancy
between frequency of TSC1 mutation and frequency of LOH
in the TSC1 gene region in bladder tumours suggests that hap-
loinsufﬁciency of TSC1 may contribute to tumour develop-
ment in some cases. LOH of chromosome 9 is a particularly
frequent event in bladder cancer and to date, TSC1 is the
only gene on 9q found to be mutated in bladder tumours.
The contribution of partial loss of TSC1 to clonal expansion
of tumour cells with 9q LOH is unknown, and haploinsufﬁ-
ciency remains a possibility in those bladder tumours with
9q LOH and no TSC1 mutation. LOH at the TSC1 locus
may accompany another event driving loss of chromosome
9. Deletion of the CDKN2A locus at 9p21, which occurs in
up to 50% of bladder tumours (56,57), or of an as yet uniden-
tiﬁed chromosome 9 tumour suppressor gene, may constitute
such a driving force. Loss of one copy of TSC1 may therefore
be an advantageous gratuitous hit or ‘passenger event’ (58).
TSC is not a cancer prone syndrome and TSC lesions very
rarely progress to malignancy. That TSC patients do not have
an increased risk of developing bladder cancer, or other spora-
dic cancers, may be explained by the requirement of cumulat-
ive genetic insults and the typically late onset of malignant
disease. The timing and order of initiating and subsequent
genetic events in hamartoma and bladder tumour development
is likely to be critical in determining malignant potential. Why
TSC1 appears to be involved in bladder cancer and not other
epithelial cancers is an unresolved question.
Frequent LOH of 9q is found in other tumour types, includ-
ing ovarian carcinoma, gallbladder carcinoma, nasopharyngeal
carcinoma and non-small cell lung cancer (59–65). However,
reports of TSC1 and TSC2 mutation status in sporadic
tumours other than bladder are very few. No mutations were
observed in sporadic glial and glioneuronal tumours or
renal cell carcinomas (66,67). Fifty-three and 39% of lung
adenocarcinomas and precursor lesions, respectively, were
Figure 6. Localization of wild-type TSC1 (A) and TSC1 Ser35Cys (B),
Phe216Ala (C) and Thr417Ile (D) mutant proteins in amino acid-starved
97-1 cells. Cells were cultured in full growth medium on highly optically
clear microscopy dishes to sub-conﬂuence and amino acid starved for 24 h.
TSC1-GFP was observed by UV microscopy of live cells. Scale bars show
100 mM.
2012 Human Molecular Genetics, 2008, Vol. 17, No. 13found to have LOH of 9q (68). Subsequently, a screen of 47
lung adenocarcinomas identiﬁed three conﬁrmed TSC1
mutations. However, LOH and mutations were not detected
simultaneously (69).
In ovarian carcinoma, gallbladder carcinoma, nasopharyn-
geal carcinoma and lung adenocarcinoma, LOH or deletion
is described in both TSC gene regions (63,68,70,71). If loss
of TSC1/2 complex function is the pathogenic effect of loss
of TSC1, it may be expected that bladder tumours would
also show loss of TSC2 function. In an LOH screen of 16p,
we have detected LOH for markers at the TSC2 locus in
16% of bladder tumours (Platt et al., in preparation). It will
be important to screen for mutations in the retained copy of
TSC2 in cases with LOH to determine whether there is also
Figure 7. TSC1 immunostaining of HCV29 Neo (A) and TSC1 (D) cell pellets, normal ureter (negative (B) and positive (E) antibody controls) and TSC1
73–77D 5( C) and TSC1 wild-type (F) bladder tumours. TSC1 staining of TSC1 missense mutant bladder tumours; TSC1 104C.G( G), 314A.G( H),
648T.A( I) and 616C.G( J–L) mutant tumours. Arrow in (H) shows normal urothelium with strong TSC1 staining adjacent to immunonegative tumour
cells. (J) to (L) show TSC1 staining in tumours resected from the same patient in 2001 (J), 2003 (K) and 2004 (L). Arrows in (K) show positive TSC1 immunor-
eactivity in von Brunn’s nests. Scale bars show 500 mM.
Human Molecular Genetics, 2008, Vol. 17, No. 13 2013an involvement of TSC2 or whether there is an important
independent role of TSC1 in urothelial cells.
MATERIALS AND METHODS
Plasmids
TSC1 (nucleotides 123–3757 with respect to Ensembl sequence
ENST00000298552) was ampliﬁed from TERT-NHUC
cDNA using the Advantage cDNA PCR kit (Clontech,
Saint-Germain-en-Laye, France) and TSC1 FWD (GAAACT-
GAAGTACCAGTTGT) and REV (GCAAGTTAACACT-
GATTGACCATC) primers. TSC1 was cloned in-frame with
a C-terminal FLAG or GFP tag in the pFB Neo retroviral
vector, a derivative of pBABE (Stratagene, Amsterdam, The
Netherlands) modiﬁed to contain the Neomycin resistance
cassette. Missense mutant constructs were generated by site-
directed mutagenesis using QuickChange (Stratagene) accord-
ing to the manufacturer’s instructions. All constructs were
fully sequenced using the BigDye
w terminator cycle sequencing
kit version 1.1 (Applied Biosystems, Warrington, UK).
Cell lines
Two urothelial cell lines with loss of function mutations in
TSC1 (24) were used in this study. 97-1 is derived from a papil-
lary myoinvasive bladder urothelial carcinoma of grade G1/2
and stage pT1/2 (72,73). 97-1 cells have a homozygous TSC1
2295C.T mutation causing premature protein truncation at
amino acid residue 692. 97-1 were maintained in Ham’s F12
medium (Invitrogen, Paisley, UK) with 1% foetal calf serum
(FCS), 1% insulin-transferrin-selenium (Sigma, Dorset, UK),
1% MEM non-essential amino acids (NEAA; Invitrogen) and
25 mM hydrocortisone (Sigma). HCV29 was established from
non-malignant ureteric epithelium of a patient with bladder
cancer (74) and contains a homozygous 384C.Tm u t a t i o n
that is predicted to cause protein truncation at residue Q55.
HCV29 were maintained in RPMI-1640 medium supplemented
with 10% FCS and 1% L-glutamine. For starvation exper-
iments, cells were washed once in PBS and cultured overnight
in medium minus all amino acids (Cancer Research UK Media
Production Services).
Retroviral transduction
Phoenix-A packaging cells (ATCC) were maintained in
Dulbecco’s modiﬁcation of Eagle’s medium (DMEM) sup-
plemented with 10% FCS and 1% L-glutamine. Phoenix-A
were transfected by incubation with 1 mg of retroviral
plasmid DNA in 3 ml siPort XP-1TM (Ambion, Huntingdon,
UK) transfection agent in 100 ml PBS for 24 h. Virus super-
natant was harvested at 48 h post-transfection. Second and
third harvests were taken subsequently at 24 h intervals.
Virus supernatant was passed through a 0.45 mM ﬁlter
(PALL, Portsmouth, UK) and was either snap frozen as
1.5 ml aliquots at –808C or used immediately. Supernatants
were diluted 1:1 with target cell line normal growth medium
and supplemented with 8 mg/ml polybrene (Sigma). Target
cells were infected at 50% conﬂuence by overnight incubation
in virus-containing medium, and were cultured for a further
24 h in full growth medium before beginning selection.
Primary and immortalized normal human urothelial cells
Primary normal human urothelial cells (NHUC) were isolated
from samples of normal ureter collected during nephrectomy
or bladder reconstruction surgery at St James’s University
Hospital, Leeds as described (75). Immortalized NHUC
(TERT-NHUC) were generated by transduction of primary
cells with the human telomerase reverse transcriptase
(TERT) gene (76). Both primary and immortalized cells
were maintained in PromoCell keratinocyte growth medium
2 (PromoCell, Heidelberg, Germany) containing 0.09 mM
CaCl2 and supplemented with 30 ng/ml cholera toxin.
Western blotting
Sub-conﬂuent cells were washed once in ice-cold phosphate
buffered saline (PBS) and lysed in RIPA buffer containing
0.1% protease and phosphatase inhibitor cocktails (Sigma).
Cell debris was pelleted by centrifugation at 12 700 g for
10 min at 48C. Protein was quantiﬁed using the BIO-RAD
protein assay (Bio-Rad Laboratories, Hemel Hempstead,
UK) and samples analysed by SDS–PAGE. Proteins were
immobilized onto Hybond-C nitrocellulose (Amersham Biosi-
cences, Little Chalfont, UK) by semi-dry electrophoretic trans-
fer. Blots were blocked in 3% non-fat dried milk in Tris
buffered saline (TBS) (0.05 M Tris; 138 mM NaCl; 2.7 mM
KCl; pH 7.6) 0.1% [v/v] Tween 20 (Sigma) for 30 min at RT
with orbital shaking. Primary antibodies were diluted in 5%
BSA (Sigma) in TBS 0.1% [v/v] Tween 20 and blots probed
for 1 h at RT or overnight at 48C with orbital shaking. Blots
were washed for 5   5 min in .4 ml/cm
2 TBS 0.1% [v/v]
Tween 20 with orbital shaking between primary and secondary
antibody incubations and before developing. Secondary HRP-
conjugated antibodies were diluted in 3% non-fat dried milk in
TBS 0.1% [v/v] Tween 20 and blots probed for 1 h at RT or
o v e r n i g h ta t4 8C with shaking. Horseradish peroxidase
(HRP)-labelled antigen was detected by chemiluminescence
using ECL Plus western blotting detection reagent (Amersham).
Primary antibodies used were anti-TSC1 (Invitrogen, Paisley,
UK) at 1:1000, anti-TSC2 C-20 (Santa Cruz Biotechnology,
CA, USA) at 1:500, anti-ribosomal phospho-S6 Ser235/6
(Cell Signaling Technology Inc., Danvers, MA, USA) at
1:3000 and anti-a tubulin (Serotec, Kidlington, UK) at 1:500.
RNA extraction
RNA was made using the RNeasyTM kit (Qiagen, Crawley,
UK) according to the manufacturer’s instructions. DNase
treated RNA was puriﬁed by RNeasy column puriﬁcation
and eluted in RNase free water. RNA was reverse transcribed
into ﬁrst-strand cDNA using SuperScriptTM II reverse tran-
scriptase and Oligo-dT primers (Invitrogen) according to the
manufacturer’s instructions.
Real time RT–PCR
Quantitation of RNA transcripts was performed by SYBR
Green assay (Applied Biosystems). In each reaction 12.5 ml
2014 Human Molecular Genetics, 2008, Vol. 17, No. 13SYBR Green reagent was combined with 1 ml cDNA and
750 nM each of TSC1 27 FWD (CAGTCAGGTTTCC
CAAAAGC) and TSC1 84 REV (GAGTTCTTGAACAGG
CAGCTG) in a volume of 20 ml. Cycle parameters were initi-
alization at 508C for 2 min, incubation at 958C for 10 min, fol-
lowed by 40 cycles of 958C for 15 s, 608C for 1 min and 958C
for 15 s. The SDHA (succinate dehydrogenase complex,
subunit A, ﬂavoprotein) gene transcript was ampliﬁed using
primers SDHA FWD; TGGGAACAAGAGGGCATCTG and
REV; CCACCACTGCATCAAATTCATG as an internal
control for each sample. Test and control reactions were
performed in triplicate and average Ct values normalized to
expression levels of uncultured urothelium or low passage cul-
tured NHUC. PCR reactions and analyses were done on the
ABI PRISM 7700 Sequence Detector (Applied Biosystems).
RT–PCR ampliﬁcation of wild-type and missense mutant
TSC1 transcripts
TSC1 fragments spanning exons 2–5 and 2–9 were ampliﬁed
from TSC1 104C.G and 314A.G mutant tumour cDNA,
respectively, in a reaction comprising 1 mg cDNA template,
0.625U AmpliTaq Gold, 1   Gold PCR Buffer, 2.5 mM
MgCl2, 200 mM each of dATP, dCTP, dGTP and dTTP and
300 nM of each primer (TSC1 1F; GAAACTGAAGTAC
CAGTTGT and TSC1 1R; GCTTGAGAGAGCTTATGCTT
or TSC1 2R; GCACACTCGATCACAACATC) in a 25 ml
volume. Cycling conditions were 958C for 5 min, 25 or 35
cycles of 958C for 40 s, 568C for 40 s and 728C for 1 min fol-
lowed by an extension step of 728C for 10 min. Ampliﬁcation
of an approximately 900 bp HPRT (hypoxanthine phosphori-
bosyl transferase 1) gene fragment served as a positive
control (reactions conditions were as previously except for
use of primers HPRT FWD; GACACTGGCAAAA
CAATGCA and REV; CTTCGTGGGGTCCTTTTCACC).
Fluorescence imaging
Cells were seeded onto IbiTreat tissue culture-treated, highly
optically clear plastic m-dishes (Thistle Scientiﬁc, Glasgow,
UK). Cells were imaged using an inverted Zeiss AxioPlan
microscope with Zeiss oil-immersion objective lenses and an
excitation/emission ﬁlterset optimized for GFP. Images were
captured using Ludl shutters and a Hamamatsu ORCA II ER
camera linked to a computer running Volocity (Improvision,
Coventry, UK).
Immunohistochemistry
Parafﬁn wax-embedded bladder tumour biopsies were
assessed for TSC1 expression by immunohistochemistry
using the streptavidin/peroxidase method. Sections were
dewaxed in xylene and rehydrated through graded ethanols
then endogenous peroxidase activity blocked in 3% hydrogen
peroxide. Antigen retrieval was done by pressure-cooking in
0.01 M citric acid buffer, pH 6.0. Slides were blocked in
avidin/biotin solutions (Vector Laboratories) followed by
normal goat serum (1:10), then incubated with TSC1
primary antibody (Epitomics; Insight Biotechnology,
Wembley, UK) at 1:100 overnight. Slides were then incubated
with goat anti-rabbit biotinylated secondary antibody
(Dako Cytomation, Glostrup, Denmark) at 1:400 for 30 min.
Antibody binding was visualized using 3,30diamino-benzidine
tetrahydrochloride (DAB, Vector Laboratories) according
to the manufacturer’s instructions. Finally, sections were
counterstained with haematoxylin, dehydrated, cleared and
mounted.
Protein stability measurements
Turnover of exogenous TSC1 protein was investigated by
inhibition of protein synthesis by cycloheximide (Sigma) treat-
ment. Cells were grown to sub-conﬂuence in full growth
medium and treated with cycloheximde at 100 mg/ml or
DMSO vehicle alone for up to 24 h. Proteasome dependence
of TSC1 turnover was determined by co-treatment with
40 mM MG-132 (Biomol, Exeter, UK) or DMSO vehicle.
For
35S pulse chase labelling, 97-1 wild-type and mutant
TSC1 cell lines were incubated for 45 min in 1 ml Ham’s
F12 minus Cys/Met (Cancer Research UK Media Production
Services) containing 1% dialysed FBS (Sigma) and sup-
plements. Cells were labelled with 250 mCi/ml
35S Pro-mix
(Amersham) for 45 min. Cells were washed with 2 ml warm
PBS and chased in Ham’s F12 complete medium (Invitrogen),
supplemented with 2 mM methionine (Sigma) and 2 mM
cysteine (Sigma). Cell lysates were prepared in RIPA lysis
buffer and clariﬁed by centrifugation. Supernatants were incu-
bated with 1.25 mg mouse anti-TSC1 IgG1 antibody (Invitro-
gen) for 1 h at 48C with rotation. Immuno-complexes were
precipitated with 50 ml protein-G sepharose incubated over-
night at 48C. Beads were washed in 1 ml ice-cold RIPA
buffer and re-suspended in 80 ml2   SDS buffer. Samples
were analysed by SDS–PAGE and autoradiography.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
We thank Dr Filomena Esteves for help with immunohisto-
chemistry and Dr Claire Taylor (Cancer Research UK
Mutation Detection Facility, Leeds) and Professor Ian
Eperon (University of Leicester) for advice on RNA splicing.
Conﬂict of Interest statement. None declared.
FUNDING
This work was funded by a Programme grant from Cancer
Research UK (C6228/A5433).
REFERENCES
1. Gomez, M., Sampson, J. and Whittemore, V. (1999) The Tuberous
Sclerosis Complex. Oxford University Press.
2. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B.,
Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J.
et al. (1997) Identiﬁcation of the tuberous sclerosis gene TSC1 on
chromosome 9q34. Science, 277, 805–808.
Human Molecular Genetics, 2008, Vol. 17, No. 13 20153. Consortium. (1993) Identiﬁcation and characterization of the tuberous
sclerosis gene on chromosome 16. The European Chromosome 16
Tuberous Sclerosis Consortium. Cell, 75, 1305–1315.
4. Cheadle, J.P., Reeve, M.P., Sampson, J.R. and Kwiatkowski, D.J. (2000)
Molecular genetic advances in tuberous sclerosis. Hum. Genet., 107,
97–114.
5. Jones, A.C., Daniells, C.E., Snell, R.G., Tachataki, M., Idziaszczyk, S.A.,
Krawczak, M., Sampson, J.R. and Cheadle, J.P. (1997) Molecular genetic
and phenotypic analysis reveals differences between TSC1 and TSC2
associated familial and sporadic tuberous sclerosis. Hum. Mol. Genet., 6,
2155–2161.
6. Povey, S., Burley, M.W., Attwood, J., Benham, F., Hunt, D., Jeremiah,
S.J., Franklin, D., Gillett, G., Malas, S., Robson, E.B. et al. (1994) Two
loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann. Hum.
Genet., 58, 107–127.
7. Knudson, A.G., Jr (1971) Mutation and cancer: statistical study of
retinoblastoma. Proc. Natl Acad. Sci. USA, 68, 820–823.
8. Henske, E.P., Scheithauer, B.W., Short, M.P., Wollmann, R., Nahmias, J.,
Hornigold, N., van Slegtenhorst, M., Welsh, C.T. and Kwiatkowski, D.J.
(1996) Allelic loss is frequent in tuberous sclerosis kidney lesions but rare
in brain lesions. Am. J. Hum. Genet., 59, 400–406.
9. Niida, Y., Stemmer-Rachamimov, A.O., Logrip, M., Tapon, D., Perez, R.,
Kwiatkowski, D.J., Sims, K., MacCollin, M., Louis, D.N. and Ramesh, V.
(2001) Survey of somatic mutations in tuberous sclerosis complex (TSC)
hamartomas suggests different genetic mechanisms for pathogenesis of
TSC lesions. Am. J. Hum. Genet., 69, 493–503.
10. Ramesh, V. (2003) Aspects of tuberous sclerosis complex (TSC) protein
function in the brain. Biochem. Soc. Trans., 31, 579–583.
11. Plank, T.L., Yeung, R.S. and Henske, E.P. (1998) Hamartin, the product
of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears
to be localized to cytoplasmic vesicles. Cancer Res., 58, 4766–4770.
12. Johnson, M.W., Emelin, J.K., Park, S.H. and Vinters, H.V. (1999)
Co-localization of TSC1 and TSC2 gene products in tubers of patients
with tuberous sclerosis. Brain Pathol., 9, 45–54.
13. Hodges, A.K., Li, S., Maynard, J., Parry, L., Braverman, R., Cheadle, J.P.,
DeClue, J.E. and Sampson, J.R. (2001) Pathological mutations in TSC1
and TSC2 disrupt the interaction between hamartin and tuberin. Hum.
Mol. Genet., 10, 2899–2905.
14. Kwiatkowski, D.J. and Manning, B.D. (2005) Tuberous sclerosis: a GAP
at the crossroads of multiple signaling pathways. Hum. Mol. Genet., 14
(Spec No. 2), R251–R258.
15. Inoki, K., Li, Y., Xu, T. and Guan, K.L. (2003) Rheb GTPase is a direct
target of TSC2 GAP activity and regulates mTOR signaling. Genes. Dev.,
17, 1829–1834.
16. Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. and Blenis, J. (2003)
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control
mTOR signaling by acting as a GTPase-activating protein complex
toward Rheb. Curr. Biol., 13, 1259–1268.
17. Adachi, H., Igawa, M., Shiina, H., Urakami, S., Shigeno, K. and Hino, O.
(2003) Human bladder tumors with 2-hit mutations of tumor suppressor
gene TSC1 and decreased expression of p27. J. Urol., 170, 601–604.
18. Edwards, J., Duncan, P., Going, J.J., Watters, A.D., Grigor, K.M. and
Bartlett, J.M. (2002) Identiﬁcation of loci associated with putative
recurrence genes in transitional cell carcinoma of the urinary bladder.
J. Pathol., 196, 380–385.
19. Hornigold, N., Devlin, J., Davies, A.M., Aveyard, J.S., Habuchi, T. and
Knowles, M.A. (1999) Mutation of the 9q34 gene TSC1 in sporadic
bladder cancer. Oncogene, 18, 2657–2661.
20. Cairns, P., Shaw, M.E. and Knowles, M.A. (1993) Initiation of bladder
cancer may involve deletion of a tumour-suppressor gene on chromosome
9. Oncogene, 8, 1083–1085.
21. Habuchi, T., Devlin, J., Elder, P.A. and Knowles, M.A. (1995) Detailed
deletion mapping of chromosome 9q in bladder cancer: evidence for two
tumour suppressor loci. Oncogene, 11, 1671–1674.
22. Simoneau, M., Aboulkassim, T.O., LaRue, H., Rousseau, F. and
Fradet, Y. (1999) Four tumor suppressor loci on chromosome 9q
in bladder cancer: evidence for two novel candidate regions at
9q22.3 and 9q31. Oncogene, 18, 157–163.
23. van Tilborg, A.A., Groenfeld, L.E., van der Kwast, T.H. and
Zwarthoff, E.C. (1999) Evidence for two candidate tumour suppressor
loci on chromosome 9q in transitional cell carcinoma (TCC) of the
bladder but no homozygous deletions in bladder tumour cell lines.
Br. J. Cancer, 80, 489–494.
24. Knowles, M.A., Habuchi, T., Kennedy, W. and Cuthbert-Heavens, D.
(2003) Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in
transitional cell carcinoma of the bladder. Cancer Res., 63, 7652–7656.
25. Au, K.S., Williams, A.T., Roach, E.S., Batchelor, L., Sparagana, S.P.,
Delgado, M.R., Wheless, J.W., Baumgartner, J.E., Roa, B.B.,
Wilson, C.M. et al. (2007) Genotype/phenotype correlation in 325
individuals referred for a diagnosis of tuberous sclerosis complex in the
United States. Genet. Med., 9, 88–100.
26. Jansen, F.E., Braams, O., Vincken, K.L., Algra, A., Anbeek, P.,
Jennekens-Schinkel, A., Halley, D., Zonnenberg, B.A., van den
Ouweland, A., van Huffelen, A.C. et al. (2007) Overlapping neurologic
and cognitive phenotypes in patients with TSC1 or TSC2 mutations.
Neurology, 70, 908–915.
27. Zhang, H., Nanba, E., Yamamoto, T., Ninomiya, H., Ohno, K.,
Mizuguchi, M. and Takeshita, K. (1999) Mutational analysis of TSC1
and TSC2 genes in Japanese patients with tuberous sclerosis complex.
J. Hum. Genet., 44, 391–396.
28. Yamashita, Y., Ono, J., Okada, S., Wataya-Kaneda, M., Yoshikawa, K.,
Nishizawa, M., Hirayama, Y., Kobayashi, E., Seyama, K. and Hino, O.
(2000) Analysis of all exons of TSC1 and TSC2 genes for germline
mutations in Japanese patients with tuberous sclerosis: report of 10
mutations. Am. J. Med. Genet., 90, 123–126.
29. Astrinidis, A., Senapedis, W. and Henske, E.P. (2006) Hamartin, the
tuberous sclerosis complex 1 gene product, interacts with polo-like kinase
1 in a phosphorylation-dependent manner. Hum. Mol. Genet., 15,
287–297.
30. Henikoff, S. and Henikoff, J.G. (1992) Amino acid substitution matrices
from protein blocks. Proc. Natl Acad. Sci. USA, 89, 10915–10919.
31. Benvenuto, G., Li, S., Brown, S.J., Braverman, R., Vass, W.C.,
Cheadle, J.P., Halley, D.J., Sampson, J.R., Wienecke, R. and DeClue, J.E.
(2000) The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses
cell growth and augments the expression of the TSC2 product tuberin by
inhibiting its ubiquitination. Oncogene, 19, 6306–6316.
32. Chong-Kopera, H., Inoki, K., Li, Y., Zhu, T., Garcia-Gonzalo, F.R.,
Rosa, J.L. and Guan, K.L. (2006) TSC1 stabilizes TSC2 by inhibiting the
interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem.,
281, 8313–8316.
33. Goncharova, E.A., Goncharov, D.A., Eszterhas, A., Hunter, D.S.,
Glassberg, M.K., Yeung, R.S., Walker, C.L., Noonan, D., Kwiatkowski,
D.J., Chou, M.M. et al. (2002) Tuberin regulates p70 S6 kinase activation
and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor
suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).
J. Biol. Chem., 277, 30958–30967.
34. Kwiatkowski, D.J., Zhang, H., Bandura, J.L., Heiberger, K.M., Glogauer, M.,
el-Hashemite, N. and Onda, H. (2002) A mouse model of TSC1 reveals
sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6
kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11, 525–534.
35. Onda, H., Crino, P.B., Zhang, H., Murphey, R.D., Rastelli, L., Gould
Rothberg, B.E. and Kwiatkowski, D.J. (2002) Tsc2 null murine
neuroepithelial cells are a model for human tuber giant cells, and show
activation of an mTOR pathway. Mol. Cell. Neurosci., 21, 561–574.
36. Buratti, E., Chivers, M., Kralovicova, J., Romano, M., Baralle, M.,
Krainer, A.R. and Vorechovsky, I. (2007) Aberrant 50 splice sites in
human disease genes: mutation pattern, nucleotide structure and
comparison of computational tools that predict their utilization. Nucleic
Acids Res., 35, 4250–4263.
37. Cartegni, L. and Krainer, A.R. (2002) Disruption of an SF2/
ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular
atrophy in the absence of SMN1. Nat. Genet., 30, 377–384.
38. Nakai, K. and Sakamoto, H. (1994) Construction of a novel database
containing aberrant splicing mutations of mammalian genes. Gene, 141,
171–177.
39. Nellist, M., van Slegtenhorst, M.A., Goedbloed, M., van den Ouweland,
A.M., Halley, D.J. and van der Sluijs, P. (1999) Characterization of the
cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for
hamartin. J. Biol. Chem., 274, 35647–35652.
40. Wei, J., Li, P., Chiriboga, L., Mizuguchi, M., Yee, H., Miller, D.C. and
Greco, M.A. (2002) Tuberous sclerosis in a 19-week fetus:
immunohistochemical and molecular study of hamartin and tuberin.
Pediatr. Dev. Pathol., 5, 448–464.
41. Yamamoto, Y., Jones, K.A., Mak, B.C., Muehlenbachs, A. and
Yeung, R.S. (2002) Multicompartmental distribution of the tuberous
2016 Human Molecular Genetics, 2008, Vol. 17, No. 13sclerosis gene products, hamartin and tuberin. Arch. Biochem.
Biophys., 404, 210–217.
42. Clements, D., Mayer, R.J. and Johnson, S.R. (2007) Subcellular
distribution of the TSC2 gene product tuberin in human airway smooth
muscle cells is driven by multiple localization sequences and is cell-cycle
dependent. Am. J. Physiol. Lung Cell. Mol. Physiol., 292, L258–L266.
43. Rosner, M., Freilinger, A. and Hengstschlager, M. (2007) Akt regulates
nuclear/cytoplasmic localization of tuberin. Oncogene, 26, 521–531.
44. York, B., Lou, D. and Noonan, D.J. (2006) Tuberin nuclear localization
can be regulated by phosphorylation of its carboxyl terminus. Mol. Cancer
Res., 4, 885–897.
45. Ali, J.B., Sepp, T., Ward, S., Green, A.J. and Yates, J.R. (1998) Mutations
in the TSC1 gene account for a minority of patients with tuberous
sclerosis. J. Med. Genet., 35, 969–972.
46. Kwiatkowska, J., Jozwiak, S., Hall, F., Henske, E.P., Haines, J.L.,
McNamara, P., Braiser, J., Wigowska-Sowinska, J., Kasprzyk-Obara, J.,
Short, M.P. et al. (1998) Comprehensive mutational analysis of the TSC1
gene: observations on frequency of mutation, associated features, and
nonpenetrance. Ann. Hum. Genet., 62, 277–285.
47. Niida, Y., Lawrence-Smith, N., Banwell, A., Hammer, E., Lewis, J.,
Beauchamp, R.L., Sims, K., Ramesh, V. and Ozelius, L. (1999) Analysis
of both TSC1 and TSC2 for germline mutations in 126 unrelated patients
with tuberous sclerosis. Hum. Mutat., 14, 412–422.
48. Young, J. and Povey, S. (1998) The genetic basis of tuberous sclerosis.
Mol. Med. Today, 4, 313–319.
49. Dabora, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J.,
Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C. et al. (2001)
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates
increased severity of TSC2, compared with TSC1, disease in multiple
organs. Am. J. Hum. Genet., 68, 64–80.
50. Jones, A.C., Shyamsundar, M.M., Thomas, M.W., Maynard, J.,
Idziaszczyk, S., Tomkins, S., Sampson, J.R. and Cheadle, J.P. (1999)
Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic
correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet.,
64, 1305–1315.
51. van Slegtenhorst, M., Verhoef, S., Tempelaars, A., Bakker, L., Wang, Q.,
Wessels, M., Bakker, R., Nellist, M., Lindhout, D., Halley, D. et al. (1999)
Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous
sclerosis complex patients: no evidence for genotype-phenotype
correlation. J. Med. Genet., 36, 285–289.
52. Nellist, M., Verhaaf, B., Goedbloed, M.A., Reuser, A.J., van den
Ouweland, A.M. and Halley, D.J. (2001) TSC2 missense mutations inhibit
tuberin phosphorylation and prevent formation of the tuberin-hamartin
complex. Hum. Mol. Genet., 10, 2889–2898.
53. Srebrow, A. and Kornblihtt, A.R. (2006) The connection between splicing
and cancer. J. Cell Sci., 119, 2635–2641.
54. Buratti, E., Baralle, M. and Baralle, F.E. (2006) Defective splicing,
disease and therapy: searching for master checkpoints in exon deﬁnition.
Nucleic Acids Res., 34, 3494–3510.
55. Krawczak, M., Thomas, N.S., Hundrieser, B., Mort, M., Wittig, M.,
Hampe, J. and Cooper, D.N. (2007) Single base-pair substitutions in
exon–intron junctions of human genes: nature, distribution, and
consequences for mRNA splicing. Hum. Mutat., 28, 150–158.
56. Baud, E., Catilina, P. and Bignon, Y.J. (1999) p16 involvement in primary
bladder tumors: analysis of deletions and mutations. Int. J. Oncol., 14,
441–445.
57. Orlow, I., Lacombe, L., Hannon, G.J., Serrano, M., Pellicer, I., Dalbagni,
G., Reuter, V.E., Zhang, Z.F., Beach, D. and Cordon-Cardo, C. (1995)
Deletion of the p16 and p15 genes in human bladder tumors. J. Natl
Cancer Inst., 87, 1524–1529.
58. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C.,
Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C. et al. (2007)
Patterns of somatic mutation in human cancer genomes. Nature, 446,
153–158.
59. Cliby, W., Ritland, S., Hartmann, L., Dodson, M., Halling, K.C., Keeney, G.,
Podratz, K.C. and Jenkins, R.B. (1993) Human epithelial ovarian cancer
allelotype. Cancer Res., 53, 2393–2398.
60. Devlin, J., Elder, P.A., Gabra, H., Steel, C.M. and Knowles, M.A. (1996)
High frequency of chromosome 9 deletion in ovarian cancer: evidence for
three tumour-suppressor loci. Br. J. Cancer, 73, 420–423.
61. Girard, L., Zochbauer-Muller, S., Virmani, A.K., Gazdar, A.F. and Minna,
J.D. (2000) Genome-wide allelotyping of lung cancer identiﬁes new
regions of allelic loss, differences between small cell lung cancer and
non-small cell lung cancer, and loci clustering. Cancer Res., 60,
4894–4906.
62. Lo, K.W., Teo, P.M., Hui, A.B., To, K.F., Tsang, Y.S., Chan, S.Y.,
Mak, K.F., Lee, J.C. and Huang, D.P. (2000) High resolution allelotype of
microdissected primary nasopharyngeal carcinoma. Cancer Res., 60,
3348–3353.
63. Okada, S., Tsuda, H., Takarabe, T., Yoshikawa, H., Taketani, Y. and
Hirohashi, S. (2002) Allelotype analysis of common epithelial ovarian
cancers with special reference to comparison between clear cell
adenocarcinoma with other histological types. Jpn. J. Cancer Res.,
93, 798–806.
64. Suzuki, K., Ogura, T., Yokose, T., Nagai, K., Mukai, K., Kodama, T.,
Nishiwaki, Y. and Esumi, H. (1998) Loss of heterozygosity in the
tuberous sclerosis gene associated regions in adenocarcinoma of the
lung accompanied by multiple atypical adenomatous hyperplasia.
Int. J. Cancer, 79, 384–389.
65. Wistuba, I.I., Maitra, A., Carrasco, R., Tang, M., Troncoso, P., Minna, J.D.
and Gazdar, A.F. (2002) High resolution chromosome 3p, 8p, 9q and 22q
allelotyping analysis in the pathogenesis of gallbladder carcinoma.
Br. J. Cancer, 87, 432–440.
66. Parry, L., Maynard, J.H., Patel, A., Clifford, S.C., Morrissey, C., Maher,
E.R., Cheadle, J.P. and Sampson, J.R. (2001) Analysis of the TSC1
and TSC2 genes in sporadic renal cell carcinomas. Br. J. Cancer, 85,
1226–1230.
67. Parry, L., Maynard, J.H., Patel, A., Hodges, A.K., von Deimling, A.,
Sampson, J.R. and Cheadle, J.P. (2000) Molecular analysis of the TSC1
and TSC2 tumour suppressor genes in sporadic glial and glioneuronal
tumours. Hum. Genet., 107, 350–356.
68. Takamochi, K., Ogura, T., Suzuki, K., Kawasaki, H., Kurashima, Y.,
Yokose, T., Ochiai, A., Nagai, K., Nishiwaki, Y. and Esumi, H. (2001)
Loss of heterozygosity on chromosomes 9q and 16p in atypical
adenomatous hyperplasia concomitant with adenocarcinoma of
the lung. Am. J. Pathol., 159, 1941–1948.
69. Takamochi, K., Ogura, T., Yokose, T., Ochiai, A., Nagai, K., Nishiwaki,
Y., Suzuki, K. and Esumi, H. (2004) Molecular analysis of the TSC1 gene
in adenocarcinoma of the lung. Lung Cancer, 46, 271–281.
70. Fang, Y., Guan, X., Guo, Y., Sham, J., Deng, M., Liang, Q., Li, H.,
Zhang, H., Zhou, H. and Trent, J. (2001) Analysis of genetic alterations in
primary nasopharyngeal carcinoma by comparative genomic
hybridization. Genes Chromosomes Cancer, 30, 254–260.
71. Nakayama, K., Konno, M., Kanzaki, A., Morikawa, T., Miyashita, H.,
Fujioka, T., Uchida, T., Miyazaki, K., Takao, S., Aikou, T. et al.
(2001) Allelotype analysis of gallbladder carcinoma associated with
anomalous junction of pancreaticobiliary duct. Cancer Lett., 166,
135–141.
72. Sarkar, S., Julicher, K.P., Burger, M.S., Della Valle, V., Larsen, C.J.,
Yeager, T.R., Grossman, T.B., Nickells, R.W., Protzel, C., Jarrard, D.F.
et al. (2000) Different combinations of genetic/epigenetic alterations
inactivate the p53 and pRb pathways in invasive human bladder cancers.
Cancer Res., 60, 3862–3871.
73. Yeager, T.R., DeVries, S., Jarrard, D.F., Kao, C., Nakada, S.Y., Moon, T.D.,
B r u s k e w i t z ,R . ,S t a d l e r ,W . M . ,M e i s n e r ,L . F . ,G i l c h r i s t ,K . W .et al. (1998)
Overcoming cellular senescence in human cancer pathogenesis. Genes Dev.,
12, 163–174.
74. Bean, M.A., Pees, H., Fogh, J.E., Grabstald, H. and Oettgen, H.F. (1974)
Cytotoxicity of lymphocytes from patients with cancer of the urinary
bladder: detection by a 3-H-proline microcytotoxicity test. Int. J. Cancer,
14, 186–197.
75. Southgate, J., Hutton, K.A., Thomas, D.F. and Trejdosiewicz, L.K. (1994)
Normal human urothelial cells in vitro: proliferation and induction of
stratiﬁcation. Lab. Invest., 71, 583–594.
76. Chapman, E.J., Hurst, C.D., Pitt, E., Chambers, P., Aveyard, J.S. and
Knowles, M.A. (2006) Expression of hTERT immortalises normal human
urothelial cells without inactivation of the p16/Rb pathway. Oncogene, 25,
5037–5045.
Human Molecular Genetics, 2008, Vol. 17, No. 13 2017